Unknown

Dataset Information

0

Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury.


ABSTRACT:

Objectives

Persistent severe acute kidney injury (PS-AKI) is associated with poor clinical outcomes. Our study attempted to evaluate the diagnostic value of chemokines for early-stage PS-AKI prediction.

Methods

According to the KDIGO criteria, 115 COVID-19 patients diagnosed with stage 2/3 AKI were recruited from the intensive care unit between December 2022 and February 2023. Primary clinical outcomes included detecting PS-AKI in the first week (≥ KDIGO stage 2 ≥ 72 h). Cytometric Bead Array was used to detect patient plasma levels (interleukin-8 (IL-8), C-C chemokine ligand 5 (CCL5), chemokine (C-X-C Motif) ligand 9 (CXCL9), and interferon-inducible protein 10 (IP-10)) of chemokines within 24 h of enrollment.

Results

Of the 115 COVID-19 patients with stage 2/3 AKI, 27 were diagnosed with PS-AKI. Among the four measured chemokines, only the IL-8 level was significantly elevated in the PS-AKI group than in the Non-PS-AKI group. IL-8 was more effective as a biomarker while predicting PS-AKI with an area under the curve of 0.769 (0.675-0.863). This was superior to other biomarkers related to AKI, including serum creatinine. Moreover, plasma IL-8 levels of >32.2 pg/ml on admission could predict PS-AKI risk (sensitivity = 92.6%, specificity = 51.1%). Additionally, the IL-8 level was associated with total protein and IL-6 levels.

Conclusion

Plasma IL-8 is a promising marker for the early identification of PS-AKI among COVID-19 patients. These findings should be validated in further studies with a larger sample size.

SUBMITTER: He Z 

PROVIDER: S-EPMC10840601 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Serum chemokine IL-8 acts as a biomarker for identifying COVID-19-associated persistent severe acute kidney injury.

He Zhi Z   Liu Jing-Jing JJ   Ma Shao-Lei SL  

Renal failure 20240202 1


<h4>Objectives</h4>Persistent severe acute kidney injury (PS-AKI) is associated with poor clinical outcomes. Our study attempted to evaluate the diagnostic value of chemokines for early-stage PS-AKI prediction.<h4>Methods</h4>According to the KDIGO criteria, 115 COVID-19 patients diagnosed with stage 2/3 AKI were recruited from the intensive care unit between December 2022 and February 2023. Primary clinical outcomes included detecting PS-AKI in the first week (≥ KDIGO stage 2 ≥ 72 h). Cytometri  ...[more]

Similar Datasets

| S-EPMC9981369 | biostudies-literature
| S-EPMC10588759 | biostudies-literature
| S-EPMC9337886 | biostudies-literature
| S-EPMC8560270 | biostudies-literature
| S-EPMC6709419 | biostudies-literature
| S-EPMC7880358 | biostudies-literature
| S-EPMC8166095 | biostudies-literature
| S-EPMC7124719 | biostudies-literature
| S-EPMC11011168 | biostudies-literature
| S-EPMC6794610 | biostudies-literature